Ziprasidone is an atypical antipsychotic, pharmacologically distinct from traditional agents like the phenothiazines or haloperidol. Atypical antipsychotics are deemed to be the standard of care for schizophrenia and related disorders, and with the exception of
clozapine, may be considered as first-line treatment options for the management of psychosis. Atypical antipsychotics are generally more efficacious in treating the negative symptoms of schizophrenia (e.g., social withdrawal, apathy) and tend to exhibit a lower incidence of extrapyramidal symptoms (EPS) than traditional agents. Placebo-controlled studies indicate that ziprasidone is significantly superior to placebo in improving positive, negative and affective symptoms of schizophrenia and schizoaffective disorder. Preliminary data suggest that ziprasidone may also have a role in the treatment of Tourette's syndrome. Ziprasidone's unique pharmacology offers advantages in the areas of antipsychotic-induced weight gain and possibly the treatment of depressive symptoms in patients with schizophrenia or schizoaffective disorder